Switch to:
Also traded in: France, Germany, Switzerland, UK
» Details

Insider Trades

Latest Guru Trades with ERFSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:NAS:DXCM, NAS:QGEN, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NAS:BRKR, NYSE:CRL, NAS:PRAH, NAS:VWR, NYSE:ALR, NAS:PRXL, OTCPK:CZMWY, NAS:INCR, NAS:NEOG, OTCPK:SSMXY, NAS:EXAS, NAS:MEDP, NAS:IDXX, NAS:MYGN » details
Traded in other countries:ERF.France, ESF.Germany, ERF.Switzerland, 0MV5.UK,
Eurofins Scientific SE is engaged in bioanalytical testing services. Its geographical areas include Benelux, France, Germany, North America, Nordic countries, UK and Ireland, and Other countries.

Eurofins Scientific SE founded in 1987, is engaged in food and pharmaceutical products testing. It services include food & feed testing, pharma services, pharma product testing, forensics & applied genetics,environmental services, agrosciences services, genomic services, forensic services and REACH services. It operates over 190 laboratories across 36 countries. The Group is organised on a worldwide basis into one main business segment: Analytical testing. It operates in seven main geographical areas. These are Benelux, France, Germany, North America, Nordic countries, UK and Ireland, and Other countries.

Ratios

vs
industry
vs
history
PE Ratio 54.85
ERFSF's PE Ratio is ranked lower than
85% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. ERFSF: 54.85 )
Ranked among companies with meaningful PE Ratio only.
ERFSF' s PE Ratio Range Over the Past 10 Years
Min: 40.63  Med: 57 Max: 75.49
Current: 54.85
40.63
75.49
Forward PE Ratio 32.36
ERFSF's Forward PE Ratio is ranked lower than
73% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. ERFSF: 32.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 54.85
ERFSF's PE Ratio without NRI is ranked lower than
83% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. ERFSF: 54.85 )
Ranked among companies with meaningful PE Ratio without NRI only.
ERFSF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 40.63  Med: 57 Max: 75.49
Current: 54.85
40.63
75.49
Price-to-Owner-Earnings 51.07
ERFSF's Price-to-Owner-Earnings is ranked lower than
74% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. ERFSF: 51.07 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ERFSF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.73  Med: 39.41 Max: 52.19
Current: 51.07
26.73
52.19
PB Ratio 5.31
ERFSF's PB Ratio is ranked lower than
66% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. ERFSF: 5.31 )
Ranked among companies with meaningful PB Ratio only.
ERFSF' s PB Ratio Range Over the Past 10 Years
Min: 4.36  Med: 5.2 Max: 6.52
Current: 5.31
4.36
6.52
PS Ratio 3.31
ERFSF's PS Ratio is ranked lower than
51% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. ERFSF: 3.31 )
Ranked among companies with meaningful PS Ratio only.
ERFSF' s PS Ratio Range Over the Past 10 Years
Min: 2.26  Med: 2.7 Max: 3.38
Current: 3.31
2.26
3.38
Price-to-Free-Cash-Flow 52.87
ERFSF's Price-to-Free-Cash-Flow is ranked lower than
77% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. ERFSF: 52.87 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ERFSF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 36.18  Med: 43.1 Max: 55.9
Current: 52.87
36.18
55.9
Price-to-Operating-Cash-Flow 22.16
ERFSF's Price-to-Operating-Cash-Flow is ranked lower than
67% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. ERFSF: 22.16 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ERFSF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 15.16  Med: 18.07 Max: 22.65
Current: 22.16
15.16
22.65
EV-to-EBIT 40.32
ERFSF's EV-to-EBIT is ranked lower than
85% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. ERFSF: 40.32 )
Ranked among companies with meaningful EV-to-EBIT only.
ERFSF' s EV-to-EBIT Range Over the Past 10 Years
Min: 28.4  Med: 34.8 Max: 42.2
Current: 40.32
28.4
42.2
EV-to-EBITDA 24.90
ERFSF's EV-to-EBITDA is ranked lower than
71% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. ERFSF: 24.90 )
Ranked among companies with meaningful EV-to-EBITDA only.
ERFSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 17.5  Med: 21.5 Max: 26.1
Current: 24.9
17.5
26.1
PEG Ratio 3.89
ERFSF's PEG Ratio is ranked lower than
55% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. ERFSF: 3.89 )
Ranked among companies with meaningful PEG Ratio only.
ERFSF' s PEG Ratio Range Over the Past 10 Years
Min: 2.03  Med: 2.94 Max: 3.89
Current: 3.89
2.03
3.89
Shiller PE Ratio 130.78
ERFSF's Shiller PE Ratio is ranked lower than
97% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. ERFSF: 130.78 )
Ranked among companies with meaningful Shiller PE Ratio only.
ERFSF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 84.82  Med: 106.53 Max: 133.65
Current: 130.78
84.82
133.65
Current Ratio 1.82
ERFSF's Current Ratio is ranked lower than
66% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ERFSF: 1.82 )
Ranked among companies with meaningful Current Ratio only.
ERFSF' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.46 Max: 2.5
Current: 1.82
1.2
2.5
Quick Ratio 1.77
ERFSF's Quick Ratio is ranked lower than
61% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ERFSF: 1.77 )
Ranked among companies with meaningful Quick Ratio only.
ERFSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.42 Max: 2.44
Current: 1.77
1.07
2.44
Days Sales Outstanding 73.02
ERFSF's Days Sales Outstanding is ranked lower than
58% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. ERFSF: 73.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
ERFSF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 73.02  Med: 84.78 Max: 100.06
Current: 73.02
73.02
100.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.37
ERFSF's Dividend Yield % is ranked lower than
91% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. ERFSF: 0.37 )
Ranked among companies with meaningful Dividend Yield % only.
ERFSF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.33  Med: 0.43 Max: 0.6
Current: 0.37
0.33
0.6
Dividend Payout Ratio 0.20
ERFSF's Dividend Payout Ratio is ranked higher than
73% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. ERFSF: 0.20 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ERFSF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.18 Max: 0.25
Current: 0.2
0.06
0.25
3-Year Dividend Growth Rate 13.90
ERFSF's 3-Year Dividend Growth Rate is ranked higher than
85% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.80 vs. ERFSF: 13.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ERFSF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.3 Max: 112.1
Current: 13.9
0
112.1
Forward Dividend Yield % 0.36
ERFSF's Forward Dividend Yield % is ranked lower than
92% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.13 vs. ERFSF: 0.36 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.58
ERFSF's 5-Year Yield-on-Cost % is ranked higher than
74% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. ERFSF: 4.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ERFSF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.08  Med: 5.32 Max: 7.43
Current: 4.58
4.08
7.43
3-Year Average Share Buyback Ratio -1.10
ERFSF's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. ERFSF: -1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ERFSF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.9  Med: -1 Max: -0.2
Current: -1.1
-1.9
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.61
ERFSF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. ERFSF: 3.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ERFSF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 2.32 Max: 3.69
Current: 3.61
0
3.69
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.28
ERFSF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
94% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.71 vs. ERFSF: 5.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.54
ERFSF's Price-to-Median-PS-Value is ranked lower than
99.99% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. ERFSF: 1.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ERFSF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.84 Max: 1.57
Current: 1.54
0
1.57
Price-to-Peter-Lynch-Fair-Value 3.37
ERFSF's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. ERFSF: 3.37 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ERFSF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 2.32 Max: 3.45
Current: 3.37
0
3.45
Earnings Yield (Greenblatt) % 2.45
ERFSF's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. ERFSF: 2.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ERFSF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.4  Med: 2.9 Max: 3.5
Current: 2.45
2.4
3.5
Forward Rate of Return (Yacktman) % 20.63
ERFSF's Forward Rate of Return (Yacktman) % is ranked higher than
87% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. ERFSF: 20.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ERFSF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 20.63  Med: 21.2 Max: 22.2
Current: 20.63
20.63
22.2

More Statistics

Revenue (TTM) (Mil) $2,565
EPS (TTM) $ 7.98
Beta0.87
Short Percentage of Float0.00%
52-Week Range $322.75 - 465.71
Shares Outstanding (Mil)16.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,679 3,027 3,386
EPS ($) 11.49 13.66 15.83
EPS without NRI ($) 11.49 13.66 15.83
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 2.43 2.85 3.38
» More Articles for OTCPK:ERFSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Eurofins Scientific SE breached its 50 day moving average in a Bullish Manner : ERFSF-US : January... Jan 16 2017
Eurofins Scientific SE – Value Analysis (US OTC:ERFSF) : January 9, 2017 Jan 09 2017
Eurofins Scientific SE breached its 50 day moving average in a Bullish Manner : ERFSF-US : January... Jan 06 2017
PerkinElmer Sells Prenatal Screening Lab Services Unit To Eurofins Scientific Apr 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK